Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback